Publications by authors named "D Ladon"

Claim this Profile
E
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.
Mithun Vinod Shah, Kevin Hung, Anmol Baranwal, Monika M Kutyna, Aref Al-Kali, Dariusz Ladon

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.
Mithun Vinod Shah, Kevin Hung, Anmol Baranwal, Gauri Wechalekar, Aref Al-Kali, Dariusz Ladon

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling facets of MECOM-associated syndrome: somatic genetic rescue, clonal hematopoiesis, and phenotype expansion.
Parvathy Venugopal, Peer Arts, Lucy C Fox, Annet Simons, Devendra K Hiwase, Dariusz Ladon

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.
Mihir D Wechalekar, Lin-Pierre Zhao, Monika M Kutyna, Lih En Hong, Joule Li, Dariusz Ladon

Blood Cancer J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Mithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, Rakchha Chhetri, Anmol Baranwal, Dariusz Ladon

Blood Cancer J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis